NCT03055286TerminatedPhase 1
A Phase 1b/2a Clinical Study of CWP232291 in Combination With Cytarabine in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML)
JW Pharmaceutical5 sites in 2 countries15 target enrollmentStarted: February 6, 2017Last updated:
Conditions
Interventions
Drugs
Trial Snapshot
- Phase
- Phase 1
- Status
- Terminated
- Sponsor
- Enrollment
- 15
- Locations
- 5
- Primary Endpoint
- Recommended Phase 2 dose
Study Overview
Brief Summary
This is a multicenter (S. Korea/US), Phase Ib, open-label, dose-finding study to assess safety, PK, PD, and preliminary efficacy of CWP232291 administered in combination with ara-C in subjects with relapsed or refractory AML.
The primary objectives in phase 2a is to assess the efficacy of CWP232291 administered in combination with cytarabine (response rate complete remission [RR-CR]/complete remission with incomplete blood count recovery [CRi]/partial remission [PR]).
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Understands and is willing to sign an informed consent form (ICF) prior to initiation of any study-specific procedure.
- •18 years of age at the time of consenting.
- •A pathologically confirmed diagnosis of AML by World Health Organization (WHO) classification that is progressing.
- •Has failed (refractory) or relapsed after no more than 2 prior regimens, and for whom for whom no other standard therapy options are available.
- •Subjects with prior autologous and allogeneic hematopoietic stem cell transplantation (allo HSCT) are eligible.
- •Adequate laboratory results including the following:
- •Serum creatinine ≤ 2.0 mg/dL
- •Total bilirubin ≤ 1.5 x upper limit of institutional normal (ULN), unless due to Gilbert's syndrome
- •Aspartate transaminase (AST) or alanine transaminase (ALT) ≤ 3 x ULN, unless due to organ leukemic involvement
- •Eastern Cooperative Oncology Group (ECOG) performance score 0-
- •The subject should be off any anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal, biologic or any investigational agents for at least 14 days or 5 half lives, whichever is greater, prior to enrollment with the exception of hydroxyurea. All prior treatment-related non-hematologic toxicities must have resolved to ≤ grade 2 prior to screening.
- •Female subject of childbearing potential (ie, premenopausal or not surgically sterile) must agree to use effective contraception from Day 1 until 28 days after the last dose of study drug, and have a negative serum or urine pregnancy test within 2 weeks prior to Day
- •Sexually active male subjects must also use effective contraception from Day 1 until 90 days after the last dose of any study drug.
- •Female subject must agree not to breastfeed at screening and throughout the study period and for 45 days after the final study drug administration. Female subject must not donate ova starting at screening and throughout the study period and for 45 days after the final study drug administration.
- •Male subject must not donate sperm starting at screening and throughout the study period and for 90 days after the final study drug administration.
- •Agree to adhere to all study protocol requirements.
Exclusion Criteria
- •Subject has BCR-ABL-positive leukemia (Chronic myeloid leukemia [CML] in blast crisis).
- •Subject is diagnosed as acute promyelocytic leukemia (APL).
- •Subject has AML secondary to prior chemotherapy.
- •Subject has active clinically significant graft versus host disease (GVHD) or is on treatment with systemic corticosteroids for GVHD (except grade 1 skin GVHD). At least 3 months must have elapsed since completion of allogeneic stem cell transplantation.
- •Subject had a myocardial infarction within 6 months of enrollment, heart failure (New York Heart Association (NYHA) Class III or IV), uncontrolled angina, severe uncontrolled ventricular arrhythmias, left ventricular ejection fraction (LVEF) ≤ 40% or evidence of acute ischemia or active conduction system abnormalities.
- •Presence of a systemic fungal, bacterial, viral or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
- •Known in tolerance and allergy to cytarabine.
- •Active central nervous system (CNS) disease.
- •Known positive status for human immunodeficiency virus (HIV) and/or active hepatitis B or C.
- •Prior exposure to CWP
- •Pregnant or breastfeeding women.
- •Suitable for imminent bone marrow transplant, or within 4 weeks of one.
- •Major surgery within 4 weeks prior to the first study dose.
- •Concurrent other malignancy, unless the patient has been disease-free for at least five years following curative intent therapy, with the following exceptions: (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally (surgery or other modality) with curative intent.
Arms & Interventions
CWP232291 in combination with cytarabine (ara-C)
Experimental
Intervention: CWP232291 (Drug)
Outcomes
Primary Outcomes
Recommended Phase 2 dose
Time Frame: up to 4 weeks
To be determinded Recommended Phase 2 dose (RP2D) of CWP232291 in combination with cytarabine (ara-C), administered to subjects with relapsed or refractory AML.
Secondary Outcomes
- AUC0-∞ as a Pharmacokinetic (PK) assessments for CWP232291(3rd Cycle (each cycle = 28 days), Cycle 1 Day 1: Pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in Part A and at Cycle 1 Day 1: Pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in Part B.)
- AUC0-τ as a Pharmacokinetic (PK) assessments for CWP232291(3rd Cycle (each cycle = 28 days), Cycle 1 Day 1: Pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in Part A and at Cycle 1 Day 1: Pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in Part B.)
- t½ as a Pharmacokinetic (PK) assessments for CWP232291(3rd Cycle (each cycle = 28 days), Cycle 1 Day 1: Pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in Part A and at Cycle 1 Day 1: Pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in Part B.)
- tmax as a Pharmacokinetic (PK) assessments for CWP232291(3rd Cycle (each cycle = 28 days), Cycle 1 Day 1: Pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in Part A and at Cycle 1 Day 1: Pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in Part B.)
- AUC0-t as a Pharmacokinetic (PK) assessments for CWP232291(3rd Cycle (each cycle = 28 days), Cycle 1 Day 1: Pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in Part A and at Cycle 1 Day 1: Pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in Part B.)
- Cmax as a Pharmacokinetic (PK) assessments for CWP232291(3rd Cycle (each cycle = 28 days), Cycle 1 Day 1: Pre, 0.5hr, 1hr, 2hr, 3hr, 4hr, 5hr, 8hr, and 24hr after the start of infusion in Part A and at Cycle 1 Day 1: Pre, 2hr, 4hr, 8hr, and 24hr after the start of infusion in Part B.)
Investigators
Study Sites (5)
Loading locations...
Similar Trials
Active, not recruiting
Phase 1
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)Multiple MyelomaNCT03989414Celgene424
Completed
Phase 1
Panobinostat and Ruxolitinib in Primary Myelofibrosis, Post-polycythemia Vera-myelofibrosis or Post-essential Thrombocythemia-myelofibrosisPost Essential Thrombocythemia MyelofibrosisPost Polycythemia-Vera MyelofibrosisIdiopathic MyelofibrosisNCT01433445Novartis Pharmaceuticals61
Terminated
Phase 2
Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-IntronAdvanced CholangiocarcinomaNCT02982720Aiwu Ruth He, MD4
Completed
Phase 1
A Study of Itolizumab (EQ001) to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity in Uncontrolled AsthmaAsthmaNCT04007198Biocon Limited18
Completed
Phase 1
Study of Two Multiple Intravitreal Doses of BAT5906 for Safety and Efficacy in Patients With Diabetic Macular EdemaDiabetic Macular EdemaNCT04772105Bio-Thera Solutions60